The $670M Debut That Just Broke Biotech's All-Time Record
Parabilis Medicines just pulled off the largest venture-backed biotech IPO in history at $670 million, one day after signing a deal with Regeneron worth up to $2.3 billion. The real story isn't just the money; it's what this says about who gets funded in biotech right now.
A Company You've Probably Never Heard Of Just Made IPO History
On Tuesday, a clinical-stage cancer biotech most people couldn't name walked onto the Nasdaq and raised $670 million. That's the largest IPO ever for a venture-backed biotech company. Not this year. Not this decade. Ever.
Parabilis Medicines, formerly known as FogPharma, priced 33.5 million shares at $20 apiece under the ticker PBLS. The stock promptly opened at $33.35, giving early buyers a 58% pop on day one before closing at $31.60. If the biotech IPO market has been a frozen lake for two years, Parabilis just drove a truck across it.
But the IPO wasn't even the biggest news of the week for this Cambridge, Massachusetts company. That came the day before.
Regeneron Came Knocking First
On the eve of its public debut, Parabilis inked a collaboration with Regeneron Pharmaceuticals worth up to approximately $2.3 billion. That's not a typo. Regeneron put down $50 million in cash upfront, committed to a $75 million private stock purchase at $18 per share (a 10% discount to the IPO price), and layered on up to $2.2 billion in milestone payments plus royalties in the low double digits.
The deal covers five initial targets, with Regeneron holding options to add more. Think of it like a streaming service buying the rights to a studio's entire slate of upcoming films: they liked the first trailer so much, they wanted the whole catalog.
Combined with the IPO, Parabilis pulled in roughly $745 million of gross proceeds in a single week. That's the kind of capital raise that makes even late-stage pharma companies blink.
What Parabilis Actually Does (And Why Investors Care)
Parabilis builds something called Helicons: tiny, corkscrew-shaped peptides engineered to slip inside cells and grab onto proteins that traditional drugs can't reach. If you think of most drugs as keys designed to fit specific locks on the outside of a cell, Helicons are more like burglars who pick the lock, walk inside, and rearrange the furniture.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The technology traces back to Harvard professor Gregory Verdine, who founded the company in 2015. His lab work in the late 1990s on stabilized helical peptides eventually became Parabilis's core platform. The company's lead drug, zolucatetide (FOG-001), targets a protein called β-catenin in the Wnt signaling pathway, a notorious driver of certain cancers that scientists have struggled to drug for decades.
Beyond zolucatetide, the Helicon platform supports three categories of therapies: inhibitors of hard-to-reach protein interactions, targeted protein degraders (molecules that tag unwanted proteins for destruction), and targeted radiopharmaceuticals (peptides that deliver radiation directly to tumor cells). The rest of the pipeline is preclinical, but the versatility of the platform is part of what's attracting so much capital.
How Parabilis Leapfrogged Every Biotech Before It
To appreciate the scale here, consider the company this IPO just dethroned. Kailera Therapeutics raised $625 million in April 2026, which at the time was the largest biotech IPO in Nasdaq history. That record stood for roughly two months. Before Kailera, the benchmark was Moderna's ~$600 million debut back in 2018, a record that survived nearly eight years.
Parabilis blew past both.
The offering was led by Leerink Partners and BofA Securities, with Evercore ISI, Guggenheim Securities, and LifeSci Capital rounding out the bookrunner lineup. Underwriters also secured a 30-day option to buy up to 5,025,000 additional shares, which could push total proceeds even higher.
An IPOX Research associate told Reuters the upsized deal was a "strong signal" that the biotech IPO pipeline was healthier than last year. The Regeneron partnership provided external validation that boosted investor confidence in the offering.
The Two-Track Market Nobody's Talking About
Parabilis's blowout debut might suggest the biotech IPO window is wide open. It's not. What's actually happening is more nuanced: the market has split into two lanes, and which lane you're in determines everything.
In Q1 2026, just six drugmakers went public, but they raised a combined $1.7 billion. The median deal size hit $287.5 million, the highest since 2021's bubble. That's fewer companies raising bigger checks, a pattern analysts at PitchBook describe as a "bifurcated reopening."
Companies with late-stage clinical data, credible paths to approval, and blue-chip partnerships (like, say, a $2.3 billion Regeneron deal) can raise unprecedented sums. Everyone else faces a much higher bar. Platform-heavy companies with early-stage pipelines and no near-term catalysts? The window is barely cracked open for them.
Generalist funds are tiptoeing back into biotech after largely exiting during the downturn. But they're picking their spots with surgical precision. Analysts expect somewhere between 25 and 35 biotech IPOs in 2026; a meaningful jump from 2025's single digits, but nowhere near the 100-plus deals that defined the 2021 frenzy.
The Backstory Wall Street Loves
Parabilis didn't arrive out of nowhere. The company raised more than $800 million privately before ever going public, including a $305 million Series F round in January 2026. Its investor roster reads like a biotech all-star team: RA Capital, Fidelity (the largest shareholder at roughly 11.3%), ARCH Venture Partners, GV (Google Ventures), T. Rowe Price, and General Catalyst, among others.
Current CEO Mathai Mammen joined in 2023 after leading R&D at Johnson & Johnson, where he contributed to 9 approved medicines. That kind of pedigree matters in a market that's demanding "proof over promise" from every company that steps up to the IPO window.
What Comes Next
Parabilis now sits on a war chest that could fund years of clinical development across multiple programs. Zolucatetide is heading toward late-stage trials, and the Regeneron collaboration adds both capital and credibility to the broader Helicon platform.
But the bigger story might be what this IPO signals for the rest of biotech. There's a backlog of IPO-ready companies that delayed their debuts during the 2024-25 drought. Many are now watching Parabilis's success and wondering if the window will stay open long enough for them to follow.
The honest answer: it depends on who you are. If you've got late-stage data, a marquee partner, and a roster of crossover investors, 2026 looks like your year. If you're still building the plane while trying to fly it, the market hasn't changed its mind about you yet.
Parabilis didn't just set a record. It drew a line between the biotech haves and have-nots, and made $670 million look like the new price of admission.
Clinical & Regulatory
4 min read
Sanofi's Plan B Just Lost Its Plan B
Sanofi just halted another late-stage trial, and it's not the first pipeline disappointment this year. With Dupixent's patents expiring around 2031 and its top successor underwhelming Wall Street, the pressure to find a Plan D is getting very real.
